Trump administration withdraws Dave Weldon's CDC nomination, while Pfizer/Arvinas report mixed breast cancer data and Roche/Zealand Pharma form $5.3B obesity partnership.
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by The Goldman Sachs Group from a “buy” rating to a “neutral” rating ...
Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback